Back to search

Article

Benefit of imatinib adjuvant therapy for patients with intermediate risk gastrointestinal stromal tumor: a multi-center retrospective analysis in China

2019-12-11

Abstract excerpt

<title>Abstract</title> <p>Background The benefit of postoperative imatinib therapy on intermediated risk gastrointestinal stromal tumor patients were still under debate. Thus, the present study aims to investigate the impact of imatinib adjuvant therapy on the prognosis of intermediate risk gastrointestinal stromal tumor patients.Methods From January 2000 to April 2018, a total of 450 intermediate risk gastroint...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3d4522f0-f75a-5d8d-abf8-a62238e3d67d
DOI
10.21203/rs.2.18623/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Benefit of imatinib adjuvant therapy for patients with intermediate risk gastrointestinal stromal tumor: a multi-center retrospective analysis in ChinaDOI 10.21203/rs.2.18623/v1
Select a neighboring publication to make it the new centre.